Ontology highlight
ABSTRACT:
SUBMITTER: Soliman HH
PROVIDER: S-EPMC5008412 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
Soliman Hatem H HH Minton Susan E SE Han Hyo Sook HS Ismail-Khan Roohi R Neuger Anthony A Khambati Fatema F Noyes David D Lush Richard R Chiappori Alberto A AA Roberts John D JD Link Charles C Vahanian Nicholas N NN Mautino Mario M Streicher Howard H Sullivan Daniel M DM Antonia Scott J SJ
Oncotarget 20160401 16
<h4>Purpose</h4>Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Secondary endpoints included response rates, pharmacokinetics, and immune correlates.<h4>Experimental design</h4>Our 3+3 phase I trial comprised 10 dose levels (200, 300, 400, 600, and 800 mg once/day; 600, 800, 1200, 1600, and 2000 mg twice/d ...[more]